Showing 111-120 of 350 grants

Title Institution Researcher Program Duration Total Award Amount
GABP regulation of human beta cell proliferation The University of Texas Health Science Center at Houston Richard Cox Cures 01-September-2024 to 31-August-2027 $200,000.00
Relationships Between Executive Function Challenges and Diabetes Technology Use Among Adults with Type 1 Diabetes The University of North Carolina at Chapel Hill Rebecca Vitale Improving Lives 01-July-2026 to 30-June-2027 $49,999.80
Structure-switching Proteins for Continuous In Vivo C-peptide Monitoring The University of North Carolina at Chapel Hill Netz Arroyo Cures 01-October-2026 to 30-September-2029 $892,203.85
Engineering B Cell–Targeted Microparticles to Induce Regulatory Immunity in Type 1 Diabetes The University of North Carolina at Chapel Hill Kristy Ainslie Cures 01-April-2026 to 31-March-2027 $200,000.00
The Development of 3-β-hydroxybutyrate binding protein based electrochemical micro-sensor and its application for CKM system The University of North Carolina at Chapel Hill Koji Sode Improving Lives 01-October-2022 to 30-September-2026 $799,999.96
Role of β-cell Golgi dysfunction in Type 1 diabetes pathogenesis The University of Iowa Samuel Stephens Cures 01-June-2024 to 31-May-2027 $750,000.00
Engineered Nanoparticles for Beta Cell-Targeted Therapeutics The University of Chicago Raghavendra Mirmira Cures 01-April-2023 to 31-August-2026 $897,822.00
Expanding the Therapeutic and Targeting Capacity of Lipid Nanoparticles for Beta-Cell Protection The University of Chicago Raghavendra Mirmira Cures 01-September-2026 to 31-August-2028 $471,201.00
A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation The University of Chicago Piotr Witkowski Cures 01-February-2024 to 31-October-2026 $250,000.00
A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation The University of Chicago Piotr Witkowski Cures 01-February-2025 to 31-January-2027 $1,500,000.00